AliveCor Secures $350 Million in Funding to Revolutionize Cardiological Care with Deep Learning Technology

AliveCor, Inc., a pioneering force in the realm of cardiological care driven by deep learning, is thrilled to announce a successful funding round that has raised an impressive $350 million. This significant capital infusion will be instrumental in furthering the company's mission to transform how heart conditions are detected and managed. Known for its FDA-cleared KardiaMobile device, AliveCor has established itself as a leader in personal ECG solutions, offering the most clinically validated technology available worldwide. The KardiaMobile 6L empowers users with the capability to instantly detect critical heart conditions, including Atrial Fibrillation, Bradycardia, and Tachycardia, making it an invaluable tool for both patients and clinicians alike. The newly acquired funds will be allocated toward advancing the development of its groundbreaking AI-enabled platform that streamlines heart monitoring processes, allowing healthcare providers to manage their patients’ heart health effectively. AliveCor remains committed to ensuring data security and compliance, holding accolades such as ISO 27001 Certification and SOC 2 Type 2 Certification, which reassures users as they navigate their heart health journey. With this new funding, AliveCor is poised to expand its reach and refine its offerings further, ensuring that cutting-edge cardiac care is accessible to a wider audience. Headquartered in Mountain View, California, AliveCor continues to innovate the landscape of personal ECG technology, reflecting their unwavering dedication to improving heart health outcomes for individuals everywhere. For further insights and updates, visit alivecor.com.